DEFA14A: STAAR Surgical Confirms Alcon Merger After Window Shop Expiration

STAAR Surgical Company announced the expiration of its 45-day window shop period without receiving any competing acquisition proposals, reinforcing its board's determination that the Alcon merger maximizes stockholder value.

Summary

• The 45-day window shop period under the merger agreement with Alcon affiliates expired on September 19, 2025, at 11:59 p.m., Eastern Time.
• No competing acquisition proposals were received despite Broadwood Partners' active exploration of alternative buyers.
• The STAAR Board's conclusion that the Alcon merger maximizes value for STAAR stockholders is reinforced by the absence of competing offers.
• The Alcon merger agreement provides STAAR stockholders with $28.00 per share in all-cash consideration.
• This consideration represents a 51% premium to STAAR's closing price on August 4, 2025, and a 59% premium to its 90-day volume weighted average price as of that date.
• STAAR's stock was trading at $18.49 prior to the announcement of the Alcon merger agreement.
• Preliminary third-quarter trends indicate that business challenges adversely impacting STAAR's financial results are continuing.
• The STAAR Board of Directors strongly recommends stockholders vote FOR the merger proposal on the WHITE proxy card.

Sentiment

Score: 8

Explanation: The filing strongly reiterates the Board's confidence in the Alcon merger, highlighting the significant premium and the failure of any competing bids to emerge, despite activist shareholder efforts. It frames the merger as the best outcome for stockholders, especially given ongoing business challenges for STAAR as a standalone entity.

Positives

• The Alcon merger offers compelling, certain, and immediate cash value of $28.00 per share to stockholders.
• The $28.00 per share represents a significant premium: 51% to the closing price on August 4, 2025, and 59% to the 90-day volume weighted average price as of that date.
• The expiration of the window shop period without competing offers validates the Board's determination that the Alcon merger maximizes stockholder value and is the best path forward.
• The window shop provision, aggressively negotiated by STAAR, allowed for acceptance of a competing proposal with a nominal 1% termination fee, demonstrating commitment to maximizing stockholder value.

Negatives

• Broadwood Partners has opposed the Alcon merger agreement, claiming other parties are interested, but no competing proposals materialized.
• Preliminary third-quarter trends signal continuing business challenges that have adversely impacted STAAR's financial results.
• If the transaction is not approved, stockholders are expected to be exposed to significant value destruction compared to the $28 per share merger value.
• STAAR's stock was trading at a lower $18.49 prior to the merger agreement announcement, indicating potential standalone valuation concerns.

Risks

• The occurrence of any event, change, or circumstances that could give rise to the termination of the Alcon merger agreement or cause the consummation of the proposed transaction to be delayed or to fail to occur.
• The failure to obtain approval of the proposed transaction from STAAR's stockholders.
• The failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers, and others with whom it does business, or on its operating results and business generally.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• Significant risks inherent in STAAR as a standalone company, including continuing business challenges adversely impacting financial results.

Future Outlook

If the Alcon transaction is not approved, STAAR expects stockholders will be exposed to significant value destruction compared to the $28 per share merger value. Preliminary third-quarter trends signal that the business challenges adversely impacting STAAR's financial results are continuing. The Board believes the Alcon merger maximizes stockholder value and is the best path forward for the company.

Management Comments

• "The expiration of the window shop period with no competing acquisition proposal reinforces the Boards conclusion that the Alcon merger maximizes value for STAAR stockholders." Stephen Farrell, CEO of STAAR.
• "Collectively, the Board and management team understand the market risks, trends, and opportunities better than Broadwood, and Broadwoods opposition to the transaction is unfounded." Stephen Farrell, CEO of STAAR.

Industry Context

This announcement highlights a trend of consolidation within the specialized medical device sector, particularly in ophthalmic surgery. A global leader in phakic IOLs like STAAR Surgical being acquired by a major diversified eye care company such as Alcon suggests a strategic move by larger players to integrate innovative technologies and expand their product portfolios. The absence of competing bids, despite an active window shop period and activist shareholder efforts, indicates that the Alcon offer was likely perceived as robust and comprehensive within the current market for such specialized assets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison to industry standards. It focuses on the premium offered by Alcon relative to STAAR's historical stock price and internal strategic evaluations.

Stakeholder Impact

• Shareholders: Will receive $28.00 per share in all-cash consideration if the merger is approved, representing a significant premium. Face potential significant value destruction if the merger is not approved.
• Employees: May experience disruption to management's attention from ongoing business operations and potential impacts on retention and hiring due to the proposed transaction.
• Customers and Suppliers: Potential effects on relationships due to the announcement and proposed transaction.

Next Steps

• STAAR stockholders are encouraged to vote FOR the merger proposal on the WHITE proxy card.
• Stockholders with questions about voting their shares should contact STAAR's proxy solicitor, Innisfree M&A Incorporated.
• Relevant documents, including the Proxy Statement, and any amendments or supplements, will be available free of charge at the SEC's website (www.sec.gov) or STAAR's investor relations website.
• The proposed transaction is subject to obtaining approval from STAAR's stockholders and certain required regulatory approvals, as well as satisfying other closing conditions.

Key Dates

Recommendation

The Board strongly recommends stockholders vote FOR the Alcon merger, which offers a compelling $28.00 per share all-cash consideration. This represents a significant premium over STAAR's pre-announcement stock price and is presented as the best path forward, especially given ongoing business challenges and the absence of any superior competing offers after an extensive window shop period. Rejecting the merger is framed as exposing stockholders to significant value destruction.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Window Shop Period, Proxy Statement, Stockholder Value, EVO ICL, Phakic IOLs, Ophthalmic Surgery, Corporate Governance